SANTO Company is a member of Polpharma international pharmaceutical group. The Company develops, produces and supplies high-quality and affordable medical products to the markets of Kazakhstan and Central Asia. SANTO is one of the leaders in the pharmaceutical market in Kazakhstan with a portfolio of more than 240 generic drugs in 12 pharmacotherapeutic groups for the treatment of diseases in various fields of therapy. The Company currently implements the largest investment project on the modernization of existing pharmaceutical industries in accordance with GMP international standards, the investment volume of which is about 108 million US dollars. The company has certificates of compliance with the international standard of Good Manufacturing Practice (GMP) for the production of oral liquid medicines, aseptic powdering of antibiotic powders of the cephalosporin group, aseptic powdering of antibiotic powders of the beta-lactam group (carbapenems), aminoglycosides and polyptide antibiotics and oral parenteral liquid medicines, production of solid oral medicines and a certificate of compliance with the Standard of Good Distribution Practice (GDP) for a pharmacy warehouse. SANTO has two representative offices – in Kyrgyzstan and Uzbekistan and exports to the markets of Russia and Mongolia, and meets the needs of the domestic market.
SANTO Member of Polpharma Group
- Chief:CEO and General Director - Jiri Urbanec